A Case of Severe Ibrutinib-Induced Liver Injury and Successful Transition to Acalabrutinib
A recent case report published in Liver International details a severe instance of drug-induced liver injury (DILI) linked to the Bruton’s tyrosine kinase inhibitor ibrutinib, a medication used in hematologic malignancies. The report describes the clinical presentation, diagnostic workup, and subsequent successful management by transitioning the patient to a different agent, acalabrutinib. This case highlights a critical, albeit rare, hepatotoxicity risk associated with a widely used oncology drug and provides a practical clinical pathway for gastroenterologists and hepatologists encountering similar cases of acute liver injury in patients on targeted therapies.
Study Significance: For specialists in hepatology and transplant hepatology, this case underscores the importance of vigilant monitoring for drug-induced liver injury in patients on novel targeted agents like ibrutinib. It provides a real-world example of a viable therapeutic alternative, acalabrutinib, which allowed for continued cancer treatment without recurrent hepatotoxicity, informing clinical decision-making for managing complex cases of DILI. This knowledge is crucial for optimizing patient safety and treatment continuity in oncology, a growing intersection with gastroenterology practice.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
